While Novartis’ Pluvicto is a blockbuster, Curium heads into talks with the FDA about the review of its rival drug candidate ...

The FDA has placed a clinical hold on RGX-121 after small nodules or cystic masses were detected in the spines of five ...

The FDA has granted a three-month extension for Capricor Therapeutics’ Duchenne muscular dystrophy hopeful deramiocel in ...

The current classifications of vaccine recommendations could imply that not all shots require the consent of patients or ...

Following a tumultuous stretch under ex-Commissioner Marty Makary, current FDA leadership is working to restore reliability, ...

Not much is known about Boehringer Ingelheim’s drug candidate, dubbed BI 3031185, though the asset has completed at least two ...

Kaos Capital in a letter to other Capricor Therapeutics shareholders called for “an immediate meeting, board change, and ...

Regeneron’s Pasatru is the second fibrodysplasia ossificans progressiva drug approved in the U.S., following the 2023 ...

The Phase 3 study is evaluating two doses of Novo’s Wegovy pill in people with obesity or overweight in combination with a ...

Workforce cuts this year at seven companies involved in recent mergers and acquisitions will cost over 1,300 employees their ...

Melanoma was slower to recur in patients receiving Merck and Moderna's mRNA vaccine with Keytruda, supporting use of the ...

If confirmed by the Senate, Heidi Overton—officially revealed Wednesday as President Donald Trump’s choice for FDA ...